AnaptysBio Inc Total Liabilities
AnaptysBio Inc total liabilities. Based on the latest financial reports, AnaptysBio Inc (ANAB) has total liabilities worth $316.94 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of AnaptysBio Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of AnaptysBio Inc (2013–2025)
Total liabilities of AnaptysBio Inc from 2013 to 2025. This chart illustrates how AnaptysBio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore AnaptysBio Inc (ANAB) investment intensity to see how much of total assets are deployed in long-term investments.
AnaptysBio Inc Competitors by Total Liabilities
The table below lists competitors of AnaptysBio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Digiwin Software Co Ltd
SHE:300378
|
China | CN¥1.18 Billion |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
|
USA | $116.94 Million |
|
Ellington Financial Inc.
NYSE:EFC
|
USA | $17.48 Billion |
|
Companhiade Eletricidade do Estado da Bahia - COELBA
SA:CEEB3
|
Brazil | R$29.65 Billion |
|
Daqo New Energy Corp ADR
NYSE:DQ
|
USA | $449.58 Million |
|
Mobileye Global Inc. Class A Common Stock
NASDAQ:MBLY
|
USA | $628.00 Million |
|
Vestjysk Bank A/S
CO:VJBA
|
Denmark | Dkr43.37 Billion |
|
Chongqing Lummy Pharmaceutical
SHE:300006
|
China | CN¥910.32 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down AnaptysBio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AnaptysBio Inc (ANAB) total assets.
Liquidity & Leverage Metrics
AnaptysBio Inc Total Liabilities Ratios Explained
AnaptysBio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 24.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AnaptysBio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AnaptysBio Inc (2013–2025)
The table below shows the annual total liabilities of AnaptysBio Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $327.19 Million | -20.77% |
| 2024-12-31 | $412.97 Million | +13.36% |
| 2023-12-31 | $364.29 Million | +4.60% |
| 2022-12-31 | $348.28 Million | +21.50% |
| 2021-12-31 | $286.64 Million | +1346.15% |
| 2020-12-31 | $19.82 Million | -34.34% |
| 2019-12-31 | $30.19 Million | +33.39% |
| 2018-12-31 | $22.63 Million | +3.90% |
| 2017-12-31 | $21.78 Million | -4.93% |
| 2016-12-31 | $22.91 Million | +64.33% |
| 2015-12-31 | $13.94 Million | -26.89% |
| 2014-12-31 | $19.07 Million | +406.02% |
| 2013-12-31 | $3.77 Million | -- |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more